New York is currently home to 4503 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
Recruiting
PAUSE 2 study is a prospective, open-label, blinded-endpoint non-inferiority RCT of PAUSE vs. ASRA management in DOAC treated high risk patients with AF/VTE who need elective high bleed risk surgery/procedure and/or any procedure involving neuraxial anesthesia. The purpose of the PAUSE 2 study is to show that PAUSE management will be as safe (i.e., non-inferior) as ASRA management, with 95% of patients having low/undetectable pre-operative DOAC levels \<30 ng/mL in each group., at the time of su... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Northwell Health System, New York, New York
Conditions: Atrial Fibrillation (AF), VTE
DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma
Recruiting
The purpose of this study is to determine the feasibility of administering DFMO to patients with relapsed Ewing sarcoma and osteosarcoma who have completed all planned therapy and have no evidence of disease.
Gender:
ALL
Ages:
39 years and below
Trial Updated:
05/06/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Osteosarcoma Recurrent, Ewing's Tumor Recurrent
mHealth-CArdiac REhabilitation for INOCA
Recruiting
This is a multi-site phase II, 2:1 pragmatic randomized trial of 250 participants within the NYU Langone Health (NYULH) and Emory University Medical Center system to evaluate mobile health cardiac rehabilitation (mHealth-CR) in patients who meet clinical criteria for INOCA (ischemia and no obstructive coronary disease on imaging). Participants will be randomized to mHealth-CR or usual care. The study intervention takes place for 3 months which is the time period for most traditional CR programs.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: NYU Langone Health, New York, New York
Conditions: Ischemia
Efficacy and Safety of VDPHL01 in Males With AGA
Recruiting
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, mont... Read More
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
05/06/2025
Locations: Site 37, Kew Gardens, New York
Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
MB-105 in Patients With CD5 Positive T-cell Lymphoma
Recruiting
This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Lymphoma, T-Cell
Starting Early to Prevent Obesity Using Telehealth (StEP OUT): Intervention Development Trial
Recruiting
The goal of this intervention development study is to optimize the Starting Early to Prevent Obesity Using Telehealth (StEP OUT) intervention for feasibility and acceptability, using human-centered design and community-engaged research methods.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Long Island Jewish Medical Center, New Hyde Park, New York
Conditions: Child Obesity, Breast Feeding, Feeding Behavior, Nutrition, Healthy
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Recruiting
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/06/2025
Locations: ACW Investigative Site 214, Albany, New York
Conditions: Dementia Moderate, Dementia, Mild, Alzheimer Disease
Stimulation for Bowel Emptying
Recruiting
The investigators are testing the effect of electrical stimulation of the rectum on colonic motility. Most individuals with spinal cord injury develop neurogenic bowel dysfunction, which includes slowed colonic motility, which means that stools take longer than normal to pass through the colon. This slowed movement may result in chronic constipation and difficulty emptying the bowels. Individuals typically (without or without caregiver assistance) insert a gloved finger into the rectum and gentl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Syracuse VA Medical Center, Syracuse, NY, Syracuse, New York
Conditions: Neurogenic Bowel Dysfunction
An Observational Research Study to Uncover Subtypes of Cancer Cachexia
Recruiting
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable). Patients with these cancer types are at risk for developing cancer cachexia (CC), which is defined as weight loss, muscle loss, and fat loss due to cancer. CC has been associated with reduced physical performance, impaired quality of life, and poorer survival. Many... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Northwell Health/Center for Advanced Medicine, Lake Success, New York
Conditions: Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Pancreatic Adenocarcinoma
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
Recruiting
This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin signaling pathway. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Westchester Medical Center, Valhalla, New York
Conditions: Colon Cancer, Metastatic Colon Cancer
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
Recruiting
The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/06/2025
Locations: Velocity Clinical Research, Binghamton, New York
Conditions: Epstein-Barr Virus Infection
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
Recruiting
This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.
Gender:
ALL
Ages:
Between 48 months and 69 months
Trial Updated:
05/06/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Attention-Deficit/Hyperactivity Disorder